Why is cabergoline banned from sale in China?

Cabergoline (Cabergoline) is a dopamine receptor agonist commonly used to treat hyperprolactinemia, Parkinson's disease, and certain hormone-related diseases. It was once widely used in clinical practice due to its remarkable efficacy and relatively low side effects. However, cabergoline is currently banned from sale in the Chinese market, mainly due to drug safety and regulatory requirements.

Cabergoline may cause serious side effects in some patients, especially the risk of heart valve disease, which has attracted great attention from regulatory authorities. Although this side effect is not common, due to its potential harm, the domestic drug regulatory agency has conducted a strict review of the safety of this drug and believes that it is difficult to ensure drug safety for all patients under existing monitoring conditions.

The import and production of cabergoline face certain approval and regulatory obstacles in China. During the drug registration process, a large amount of clinical data needs to be submitted to prove safety and effectiveness. However, because the relevant data and risk assessment have not yet fully met national standards, the approval of the drug in the Chinese market has been blocked. In addition, the existence of alternative medicines also makes regulatory authorities more cautious.

Domestic drug management policies pay more and more attention to drug safety and patient medication risks, emphasizing strict review and follow-up monitoring. Based on the above multiple factors, cabergoline is banned from sale in China to protect public health and drug safety. If patients require similar treatment, they should consult their doctor promptly and choose other safe and effective alternatives.

Reference materials:https://my.clevelandclinic.org/health/drugs/20863-cabergoline-tablets